title: [The expression of thymidylate synthase (TS) and excision repair complementing-1 (ERCC-1) protein in patients with unresectable colorectal cancer treated with mFOLFOX6 therapy].
abstract: Thymidylate synthase (TS) and excision repair complementing-1 (ERCC-1) were known to be important biomarkers to predict a tumor response to 5-fluorouracil (5-FU) and oxaliplatin, but the relationship between these expressions and tumor response were still unclear. The aim of this study was to determine whether the expression of TS and ERCC-1 protein predict a tumor response in patients with unresectable colorectal cancer treated with mFOLFOX6 therapy as first-line treatment. Fifty patients with unresectable colorectal cancer treated with mFOLFOX6 therapy were enrolled in this study. The expression of TS and ERCC-1 protein in primary cancer cells were examined using immunohistochemistry. There were no significant differences between response rate and the expression of TS or ERCC-1 protein (TS: p>0.99, ERCC-1: p= 0.50). There were no significant differences between progression-free survival time and the expression of TS or ERCC-1 protein (TS: p=0.60, ERCC-1: p=0.60). In this study, the expression TS and ERCC-1 protein may not be useful for the prediction of tumor response in patients with unresectable colorectal cancer treated with mFOLFOX6 therapy.
authors.affiliation: Dept. of Digestive Tract and General Surgery, Saitama Medical Center, Saitama Medical University.
authors.forename: Keiichiro
authors.initials: K
authors.lastname: Ishibashi
authors.forename: Norimichi
authors.initials: N
authors.lastname: Okada
authors.forename: Toru
authors.initials: T
authors.lastname: Ishiguro
authors.forename: Kouki
authors.initials: K
authors.lastname: Kuwabara
authors.forename: Tomonori
authors.initials: T
authors.lastname: Ohsawa
authors.forename: Masaru
authors.initials: M
authors.lastname: Yokoyama
authors.forename: Kensuke
authors.initials: K
authors.lastname: Kumamoto
authors.forename: Norihiro
authors.initials: N
authors.lastname: Haga
authors.forename: Takashi
authors.initials: T
authors.lastname: Mori
authors.forename: Hirofumi
authors.initials: H
authors.lastname: Yamada
authors.forename: Ichiro
authors.initials: I
authors.lastname: Miura
authors.forename: Junichi
authors.initials: J
authors.lastname: Tamaru
authors.forename: Shinji
authors.initials: S
authors.lastname: Itoyama
authors.forename: Hideyuki
authors.initials: H
authors.lastname: Ishida
mesh_terms: D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D015415:Biomarkers / Q000032:analysis*; D015179:Colorectal Neoplasms / Q000737:chemistry* / Q000188:drug therapy*; D004268:DNA-Binding Proteins / Q000032:analysis*; D004720:Endonucleases / Q000032:analysis*; D005260:Female; D005472:Fluorouracil / Q000627:therapeutic use; D006801:Humans; D007150:Immunohistochemistry; D002955:Leucovorin / Q000627:therapeutic use; D008297:Male; D008875:Middle Aged; D009944:Organoplatinum Compounds / Q000627:therapeutic use; D013940:Thymidylate Synthase / Q000032:analysis*; D016896:Treatment Outcome
chemical_list: D015415:Biomarkers; D004268:DNA-Binding Proteins; D009944:Organoplatinum Compounds; D013940:Thymidylate Synthase; C071447:ERCC1 protein, human; D004720:Endonucleases; D002955:Leucovorin; D005472:Fluorouracil